Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a Canada-based global medical cannabis company with shares listed on NASDAQ and the Toronto Stock Exchange. From an investor and industry perspective, Aurora’s news flow centers on medical cannabis expansion, scientific research, international market development and operational performance.
Company announcements frequently highlight growth in global medical cannabis revenue, leadership positions in key markets, and updates on its plant propagation business through Bevo Farms Ltd. Earnings releases and financial updates provide detail on segment performance across medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA and working capital trends.
News items also cover Aurora’s international initiatives, such as investments in its EU-GMP manufacturing facility in Leuna, Germany, launches of proprietary medical flower cultivars in Poland under the Cannabis flos Aurora brand, and the introduction of the Daily Special medical brand in Germany. In Australia, updates include distribution partnerships through MedReleaf Australia and Leafio, aimed at expanding access to Aurora’s medical cannabis products via pharmacy networks.
Scientific and educational developments are another recurring theme. Aurora reports progress in powdery mildew resistance research (PM2) conducted at its Aurora Coast R&D facility, including breeding programs and production trials. The company also announces collaborations like the Physician Experience Platform (PEP) with Copeia, which provides anonymized, peer-reviewed medical cannabis case studies for physicians in multiple countries.
Investors following ACB news can expect coverage of quarterly results, international facility investments, product launches, distribution agreements, conference participation and medical education initiatives. Bookmark this page to monitor how Aurora’s strategic focus on global medical cannabis, science and international markets is reflected in its ongoing news and disclosures.
Aurora Cannabis Inc. has entered a strategic supply agreement with Cantek Holdings, a leader in Israeli medical cannabis, to supply a minimum of 4,000 kgs of dried bulk flower annually for two years, with an option to extend. The co-branded products are aimed at the Israeli market, which is a major importer of medical cannabis. This move positions Aurora in key international markets alongside Germany. The initial shipment occurred on November 16, 2020, enhancing Aurora's brand presence in Israel.
Tikun Olam and Pincanna have partnered to bring Tikun's acclaimed cannabis products to Michigan by Spring 2021. This collaboration aims to leverage Tikun Olam's extensive research on cannabis, including strains such as Avidekel, Midnight, and Erez, alongside Pincanna's expertise in product formulation. Established in 2005, Tikun Olam is recognized globally for its medical cannabis innovations. The partnership emphasizes a commitment to wellness and aims to enhance the accessibility of quality cannabis products for Michigan consumers.
Aurora Cannabis Inc. announced the closing of its overnight marketed public offering, raising US$172.5 million by selling 23 million Units at US$7.50 per Unit. The offering included 3 million Units from the exercise of the underwriters' over-allotment option. Each Unit comprises one common share and one-half common share purchase warrant, exercisable at US$9.00 for 40 months. Proceeds will be allocated towards growth opportunities, working capital, and general corporate purposes.
Aurora Cannabis has successfully completed an overnight marketed public offering, raising US$172.5 million from the sale of 23 million Units at US$7.50 per Unit. This includes the full exercise of the underwriters’ over-allotment option for 3 million Units. Each Unit comprises one common share and half a warrant, allowing for purchase of shares at US$9.00 within 40 months. The proceeds will be utilized for growth opportunities, working capital, and general corporate purposes. The Offering is conducted under the regulatory framework in Canada and the U.S.
Aurora Cannabis Inc. (ACB) announced results from its Annual General and Special Meeting held on November 12, 2020. A total of 48,828,603 shares, representing 40.34% of the issued shares, were represented at the meeting. Key approvals included the election of directors, the appointment of KPMG LLP as auditors, and the renewal of a 10% rolling stock option plan. Notably, Miguel Martin secured 90.05% of votes in favor of his position. The company remains a global cannabis leader, dedicated to serving both medical and consumer markets.
Aurora Cannabis Inc. (ACB) has announced a public offering of 20 million units at US$7.50 per unit, expected to raise US$150 million. Each unit includes one common share and one half of a common share purchase warrant, exercisable for 40 months at US$9.00. The offering will close on or about November 16, 2020, subject to market conditions. The net proceeds will fund growth opportunities and general corporate purposes. Additionally, underwriters have a 30-day option to purchase an additional 15% of the units offered. The offering is managed by BMO Capital Markets and ATB Capital Markets.
Aurora Cannabis (ACB) has announced a proposed overnight marketed public offering of units at US$7.50 per unit, aiming to raise approximately US$125 million. Each unit consists of one common share and half a warrant, with an exercise price of US$9.00 for the warrants. The offering's final terms will be established at pricing, subject to market conditions and approvals from relevant exchanges. The funds raised will be used for growth opportunities and general corporate purposes. A 30-day option for underwriters to purchase an additional 15% of the units is also planned.
Aurora Cannabis (ACB) reported Q1 2021 net revenue of $67.8 million, a slight increase from the previous quarter, driven by strong growth in the international medical market, which rose 41%. The company's medical cannabis revenue was $33.5 million while consumer cannabis revenue dipped to $34.3 million, a 3% decline. Notable achievements include an adjusted gross margin of 48% and improved liquidity, with a cash balance of approximately $250 million. However, an adjusted EBITDA loss of $57.9 million was reported, primarily due to restructuring costs.
Aurora Cannabis (ACB) has filed a final short form base shelf prospectus with Canadian regulators and the SEC, enhancing financial flexibility for business objectives. The company reaffirms its fiscal Q1 expectations, predicting cannabis net revenue between $60 million and $64 million, slightly down from $67.5 million in Q4 2020. Aurora expects to maintain compliance with financial covenants and anticipates SG&A costs around $40 million. The company aims for positive adjusted EBITDA in Q2 2021, following the divestiture of non-core subsidiaries.
Aurora Cannabis Inc. (ACB) announced a conference call on November 9, 2020, at 8:30 a.m. ET to discuss its first quarter fiscal year 2021 results, ending September 30, 2020. The financial results will be released before market open on the same day. Furthermore, Aurora has updated its director compensation plans, capping non-employee director equity compensation at $150,000, with a maximum of $97,500 in stock options. A new Performance Share Unit Plan is subject to shareholder approval on November 12, 2020.